Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study

Krzysztof Selmaj, David K.B. Li, Hans Peter Hartung, Bernhard Hemmer, Ludwig Kappos, Mark S. Freedman, Olaf Stüve, Peter Rieckmann, Xavier Montalban, Tjalf Ziemssen, Lixin Zhang Auberson, Harald Pohlmann, Francois Mercier, Frank Dahlke, Erik Wallström

Research output: Contribution to journalArticlepeer-review

212 Scopus citations

Fingerprint

Dive into the research topics of 'Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science